|
| Press Releases |
|
 |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイとバイオジェン、「LEQEMBI」（レカネマブ）が香港においてアルツハイマー病治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）と バイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、 CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、ヒト化抗ヒト可溶性 アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（香港製品名：「樂意保(R)」、一般名：レカネマブ）について、香港衛生署（Department of Health）より新薬承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
|
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 |
| エーザイ株式会社とバイオジェン・インクは、このたび、ヒト化抗ヒト可溶性アミロイドβ（Aβ）凝集体モノクローナル抗体「レケンビ(R)」（一般名：レカネマブ）について、静注（IV）維持投与に関する生物製剤承認一部変更申請（sBLA）が米国食品医薬品局（FDA）に受理されたことをお知らせします。 more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
|
エーザイ、TIME 誌による「最も影響力のある 100 社（TIME100 MOST INFLUENTIAL COMPANIES）」に選定 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、米国 TIME誌が選出する「TIME100 Most Influential Companies of 2024」に選定されたことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
GF Securities Announces its 2024 Interim Results
Aug 31, 2024 12:12 HKT/SGT
|
|
|
廣發證券公佈2024年度中期業績
Aug 31, 2024 11:54 HKT/SGT
|
|
|
广发证券公布2024年度中期业绩
Aug 31, 2024 11:47 HKT/SGT
|
|
|
卓悅集團公佈2024年中期業績
Aug 31, 2024 11:19 HKT/SGT
|
|
|
卓悦集团公布2024年中期业绩
Aug 31, 2024 11:11 HKT/SGT
|
|
|
Celeb-red our Nation's Birthday with LAC!
Aug 31, 2024 09:00 HKT/SGT
|
|
|
Gome Retail Continue to Focuses on Main Business, Actively Innovates and Transforms to Reduce Costs and Increase Efficiency
Aug 30, 2024 23:32 HKT/SGT
|
|
|
國美零售持續聚焦主業 積極創新轉型降本增效
Aug 30, 2024 23:27 HKT/SGT
|
|
|
GVRenting Unveils Sustainable Solutions in Urban Architecture
Aug 30, 2024 23:19: JST
|
|
|
国美零售持续聚焦主业 积极创新转型降本增效
Aug 30, 2024 23:14 HKT/SGT
|
|
|
聯控（3396. HK）半年收入升16% 發展新質生產力應挑戰
Aug 30, 2024 23:00 HKT/SGT
|
|
|
联控（3396.HK）半年收入升16% 发展新质生产力应挑战
Aug 30, 2024 22:45 HKT/SGT
|
|
|
Legend Holdings Recorded a Revenue of RMB233.4 Billion in H1 2024
Aug 30, 2024 22:41 HKT/SGT
|
|
|
着力发展新质生产力 联想控股2024上半年收入2,334亿元
Aug 30, 2024 22:38 HKT/SGT
|
|
|
Inkeverse Group Announces 2024 Interim Financial Results
Aug 30, 2024 22:29 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
